Vor Biopharma Inc. (VOR) NASDAQ
13.68
-0.895(-6.14%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
13.68
-0.895(-6.14%)
Currency In USD
| Previous Close | 14.57 |
| Open | 14.36 |
| Day High | 14.37 |
| Day Low | 13.63 |
| 52-Week High | 65.8 |
| 52-Week Low | 3.62 |
| Volume | 798,305 |
| Average Volume | 1.02M |
| Market Cap | 93.62M |
| PE | -0.19 |
| EPS | -70.4 |
| Moving Average 50 Days | 15.12 |
| Moving Average 200 Days | 19.71 |
| Change | -0.91 |
Vor Bio to Participate in the 46th Annual TD Cowen Health Care Conference
GlobeNewswire Inc.
Feb 23, 2026 1:00 PM GMT
BOSTON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will be presenting and hosting 1x1 investor meetings at the 46th Annu
Vor Bio to Participate in the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 06, 2026 1:00 PM GMT
BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will be presenting and hosting 1x1 investor meetings at the 44th Annu
Vor Bio Appoints RA Capital’s Andrew Levin, M.D., Ph.D., and Forbion’s Wouter Joustra to Board of Directors
GlobeNewswire Inc.
Dec 23, 2025 9:01 PM GMT
BOSTON, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Vor Biopharma Inc. (Nasdaq: VOR), a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today announced the appointment of Andrew Levin, M.D., Ph.D.,